Last reviewed · How we verify

NCT04912180: ARS

Apple Respiratory Study

Terminated Last updated 14 July 2021
What this trial tests

trial in Acute Respiratory Infection in 108 participants. Terminated before completion.

Timeline
6 April 2021
Primary endpoint
9 June 2021
9 June 2021

Quick facts

Lead sponsorApple Inc.
StatusTerminated
Study typeOBSERVATIONAL
Enrollment108
Start date6 April 2021
Primary completion9 June 2021
Estimated completion9 June 2021
Sites1 location across United States

Conditions studied

Sponsor

Apple Inc. — full company profile →

Who can join

22 and older, any sex, with Acute Respiratory Infection or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Apple Respiratory Study, a collaboration between researchers at Apple Inc. (the "Study Sponsor" or "Sponsor") and the Seattle Flu Study team at the University of Washington (UW) (the "UW Study Team"), is a prospective, longitudinal cohort, low risk Study to collect certain data from Apple Watch and iPhone to determine whether such data can detect physiologic and non-physiologic changes in individuals associated with respiratory illnesses due to influenza, SARS-CoV-2 and other respiratory pathogens (the "Study").

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Überwachungskapitalistische Biopolitik: Big Tech und die Regierung der Körper Surveillance-capitalist biopolitics: big tech and the governing of bodies
    Maschewski F, Nosthoff A. · · 2022

Verify or expand the search:

Other recruiting trials for Acute Respiratory Infection

Currently open trials in the same condition.

Other Apple Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04912180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing